EXPERIMENTAL MODELS
Contributor Information
- Name Ian Tomlinson
- Institute Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Tool Details
- Tool name: FH1 KO Mouse
- Tool type: Experimental models
- Tool sub-type: Mouse
- Disease: Renal cyst; HLRCC
- Model: Knock-Out
- Conditional: Yes
- Conditional description: LoxP flanking exons 2 and 3 of Fh1
- Genetic background and cross history: Following generation of the targeting construct, linearization, and electroporation into 129Sv/J ES cells, stable integrants were selected in 0.2 mg/ml Geneticin G418 medium. Homologous recombinants were identified initially by PCR and subsequently by Southern blot analysis. Targeted ES cells were injected into C57/BL6 blastocysts. ES cell clones were screened for 50 and 30 site-specific genomic integration of the targeting construct using a PCR-based assay and LATaq (Takara). PCR genotypes to assay Flp- and Cre-mediated recombination, and genotyping of eFlp and Cre expression mice were carriedout using standard conditions. For the genotyping of Fh1 to distinguish between wild-type, null, and floxed alleles, a common forward primer (50-GCTCAGTCACCCATCCAAAT-30 ) and differential reverse primers (50-ACCCTGCTAGGTGTCACCAC-30 and 50-CCTGGCACTGCAGACTACAA-30 ) were used
- Phenotype: Fh1-/- mice died in early embryogenesis Fh1 fl/fl with Ksp1.3/Cre are healthy until ~8 months when polyuric renal failure occurs. Postmortem shows macroscopic renal cysts.
- Description: Germline mutations in the fumarate hydratase tumour suppressor gene predispose to leiomyomatosis, renal cysts, and renal cell cancer (HLRCC). Fh1-deficient mice develop renal cysts that have an activated hypoxia pathway, with overexpression of Hif1alpha and Hif2alpha. Hif targets, such as Glut1 and Vegf were also upregulated. Therefore the mouse may be useful for testing therapeutic interventions that target angiogenesis and HIF-prolyl hydroxylation.
- Research area: Cancer; Cell Signaling & Signal Transduction; Genetic studies; Metabolism
- Production details: Following generation of the targeting construct, linearization, and electroporation into 129Sv/J ES cells, stable integrants were selected in 0.2 mg/ml Geneticin G418 medium. Homologous recombinants were identified initially by PCR and subsequently by Southern blot analysis. Targeted ES cells were injected into C57/BL6 blastocysts. ES cell clones were screened for 50 and 30 site-specific genomic integration of the targeting construct using a PCR-based assay and LATaq (Takara). PCR genotypes to assay Flp- and Cre-mediated recombination, and genotyping of eFlp and Cre expression mice were carriedout using standard conditions. For the genotyping of Fh1 to distinguish between wild-type, null, and floxed alleles, a common forward primer (50-GCTCAGTCACCCATCCAAAT-30 ) and differential reverse primers (50-ACCCTGCTAGGTGTCACCAC-30 and 50-CCTGGCACTGCAGACTACAA-30 ) were used
- For Research Use Only
Target Details
- Target: Fumarate Hydratase 1
Application Details
Handling
- Shipping conditions: Embryo/Spermatoza- Dry Ice
Documentation
- Available on request
References
- • Bardella et al. 2011. J Pathol. 225(1):4-11. PMID: 21630274.
- • Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
- • Pollard et al. 2007. Cancer Cell. 11(4):311-9. PMID: 17418408.
- • Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway.
.svg)
Availability: 
.svg)
.svg)
